Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05776251 · ClinicalTrials.gov registry record · NA

taVNS for Persistent Symptoms From Lyme Disease

A NA study of Post-Treatment Lyme Disease, sponsored by Columbia University.

Recruiting
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT05776251 is a NA study of Post-Treatment Lyme Disease that is actively recruiting participants, run by Columbia University. The registered enrollment target is 12 participants, below the 56-participant average among 4 other Post-Treatment Lyme Disease trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05776251, a NA study of Post-Treatment Lyme Disease, is actively recruiting participants, sponsored by Columbia University.

RECRUITING
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This study is one of the first studies to investigate a non-antibiotic approach to the treatment of symptoms that persist after antibiotic treatment for Lyme disease (PTLS). Transcutaneous auricular vagus nerve stimulation (taVNS) offers the potential of being an effective and non-toxic approach to reduce the burden of multisystem symptoms in patients with PTLS. This study seeks to address an important goal: to assess the safety, feasibility, and tolerability of a new non-invasive, non-pharmacologic treatment for patients with symptoms that persist despite prior antibiotic treatment for Lyme disease.

Interventions

  • DEVICE taVNS

Study Locations (1)

New York

  • Lyme and Tick-Borne Diseases Research Center - New York

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2023-05-08
Est. Completion 2026-08
Phase NA

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT05776251

The ClinicalTrials.gov registry entry for NCT05776251 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 56-participant average among 4 other Post-Treatment Lyme Disease trials with a reported enrollment target (79% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Post-Treatment Lyme Disease appearing as the primary indexed condition, and to 1 intervention - of which taVNS is the first listed.

NCT05776251 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05776251 about?

NCT05776251 is a clinical study titled "taVNS for Persistent Symptoms From Lyme Disease". This study is one of the first studies to investigate a non-antibiotic approach to the treatment of symptoms that persist after antibiotic treatment for Lyme disease (PTLS). Transcutaneous auricular vagus nerve stimulation (taVNS) offers the potential of being an effective and non-toxic approach to ...

What is the current status of trial NCT05776251?

This trial is currently recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2023-05-08. Estimated completion is 2026-08.

What conditions does trial NCT05776251 study?

This clinical trial studies the following conditions: Post-Treatment Lyme Disease.

What interventions are being tested in trial NCT05776251?

The interventions under investigation include: taVNS (DEVICE).

Who is sponsoring clinical trial NCT05776251?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05776251 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Post-Treatment Lyme Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.